Market Overview

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Cocrystal Pharma, Inc. – COCP (formerly BioZone Pharmaceuticals, Inc. - BZNE)


Rosen Law Firm, a global investor rights law firm, announces it is
investigating potential securities claims on behalf of shareholders of
Cocrystal Pharma, Inc. (NASDAQ:COCP) and of Cocrystal's predecessor,
BioZone Pharmaceuticals, Inc., resulting from allegations that Cocrystal
and BioZone may have issued materially misleading business information
to the investing public.

On September 7, 2018, the U.S. Securities and Exchange Commission
("SEC") filed a lawsuit against former officers of BioZone as well as
other individuals and corporations, alleging violations of the federal
securities laws. The SEC complaint alleges that defendants were
participants in "highly profitable ‘pump-and-dump' schemes . . . from
2013 through 2018" in the stock of three public companies, including
BioZone, that, "while enriching Defendants by millions of dollars, left
retail investors holding virtually worthless shares." On this news,
Cocrystal's share price fell $0.54 or over 14% on September 7, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Cocrystal and BioZone investors. If you purchased shares of
Cocrystal and/or BioZone please visit the firm's website at
to join the class action. You may also contact Phillip Kim or Zachary
Halper of Rosen Law Firm toll free at 866-767-3653 or via email at

Follow us for updates on LinkedIn:
or on Twitter:

Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class
Action Services for number of securities class action settlements in
2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!